Immuno Oncology Overview

Description: This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions.

Highlights:

Datamonitor Healthcare anticipates that the PD-1/PD-L1 class will gain approvals for multiple tumor types, and that this class will be the most commercially successful immuno-oncology class over the next 10 years. As monotherapies, PD-1 inhibitors will become the first-line treatment of choice in melanoma, and they are also likely to gain further approvals for a wide variety of cancers.

CAR-T cell therapy early clinical results are extremely promising. The leading CD19-targeted CAR-T treatments from Novartis, Juno, and Kite all provide response rates hovering around 90% for patients with multiply relapsed or refractory acute lymphoblastic leukemia.

Expectations for cancer vaccines have diminished after multiple failures. In theory, a cancer vaccine treatment should be able to strengthen the immune response against a cancer and help to prevent it from recurring. In practice, a series of Phase III studies investigating cancer vaccines have failed to meet their primary endpoints, and the potential future role of this class has diminished with each trial failure.

What's included in this report?

- Three fully transcribed key opinion leader interviews
- Coverage of the key immuno-oncology targets include key clinical trial results and a summary of deals related to that class
- 10-year sales forecasts are included for Yervoy, Opdivo, Keytruda, MEDI4736, and RG7446
- Development focus map shows which targets are being investigated by each of the 63 companies with immuno-oncology drugs in development.

Key questions answered:

- What are the key immuno-oncology products in development?
- What important clinical trial results have been reported for drugs in each immuno-oncology drug class?
- What specific targets and therapy approaches are the developers in this field focusing on?
- What factors could limit the commercial potential of immuno-oncology drugs in development?
- What recent deals have taken place that are related to the field of immuno-oncology?

Contents:

1. Immuno-oncology overview
2. Interviews
3. CTLA-4
4. PD-1/PD-L1
5. TIM3
6. LAG3
7. OX40
8. CD40
9. CAR-T cell therapy
10. T-cell receptor gene therapy
11. Dendritic cell therapy
12. CSF1R
13. IDO
14. CEA
Ordering:  
Order Online - http://www.researchandmarkets.com/reports/3445976/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Immuno Oncology Overview
- Web Address: http://www.researchandmarkets.com/reports/3445976/
- Office Code: SCBR12ZX

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 7500</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 18750</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- Title: 
  - Mr [ ]  Mrs [ ]  Dr [ ]  Miss [ ]  Ms [ ]  Prof [ ]
- First Name: ____________________________  Last Name: ____________________________
- Email Address: * ____________________________
- Job Title: ____________________________
- Organisation: ____________________________
- Address: ____________________________
- City: ____________________________
- Postal / Zip Code: ____________________________
- Country: ____________________________
- Phone Number: ____________________________
- Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World